

American Academy of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

Disclosure of Commercial Support for AAP CME Activities

The AAP gratefully acknowledges support for the 2024 National Conference & Exhibition. The full list of supporters can be found here: <https://aapexperience.org/education-supporters/>

Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities Grid

The AAP recognizes that there are a variety of financial relationships between individuals and ineligible companies that require review to identify possible conflicts of interest in a CME activity. The "AAP Policy on Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities" is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and mitigating all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. AAP has taken steps to mitigate any potential conflicts of interest. The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to mitigate them prior to the CME activity are implemented in ways that are consistent with the public good. The AAP is committed to providing learners with commercially unbiased CME activities.

All AAP CME activities will strictly adhere to the *Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education*. In accordance with these Standards, the following decisions will be made free of the control of an ineligible company: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Alaish, Samuel	Faculty	Yes	Global Life Sciences: Consultant
Alexander, Joshua	Faculty	Yes	Argenx: Consultant
Anderson, William	Faculty	Yes	Sanofi: Advisory Board Member; Regeneron: Advisory Board Member; Genentech: Advisory Board Member
Andras, Lindsay	Faculty	Yes	Medtronic: Consultant; Nuvasive: Consultant; Eli Lilly: Stockholder; Orthopediatrics: Consultant
Barnett, Elizabeth	Faculty	Yes	Sobi: Consultant; Pfizer: Principal Investigator; GSK: Principal Investigator
Barry, Jim	Faculty	Yes	Aerogen, Inc: Principal Investigator
Beam, Kristyn	Faculty	Yes	Chiesi Pharmaceuticals: Research Grant
Bhatia, Rajeev	AAP Section/Council Program Chair	Yes	Merck Manual: Consultant
Bird, Andrew	Moderator	Yes	DBV Technologies: Consultant; Genentech: Consultant, Research Grant; Hanimune Therapeutics: Consultant; In infant Health: Independent Study Monitor; Novartis: Consultant; Parexel: Consultant; Aimmune Therapeutics: Independent Contractor; Siolta: Independent Contractor
Braham, Sabrina	Faculty	Yes	Coral Care: Advisory Board Member; Insite Health: Advisory Board Member; Silicon Valley Therapeutics: Advisory Board Member; Wellio.Health: Employee/Owner
Branco, Nelson	Faculty	Yes	Otonexus Medical Technologies: Consultant
Bryant, Kristina	Faculty	Yes	Pfizer: Principal Investigator; Enanta: Principal Investigator; Gilead: Principal Investigator
Chaffee, Tonya	Planning Group	Yes	Organanon: Honorarium; Hologic: Consultant
Champaigne, Neena	Faculty	Yes	Amgen: Advisory Board Member; Cycle Pharma: Advisory Board Member;
Chang, Todd	Faculty	Yes	i3Simulations, Inc.: Advisory Board Member
Clayotn, Douglass	Faculty	Yes	Eli Lilly: Stockholder; Bristol Meyers Squibb: Stockholder

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Cruz, Andrea	Faculty	Yes	Pfizer: Research Grant
Davis, Alexis	AAP Section/Council Program Chair	Yes	Lansing, Inc: Advisory Board Member
De La Uz, Caridad	Moderator	Yes	Solid Biosciences: Advisory Board Member; AltaThera: Advisory Board Member
Decker, Jamie	Faculty	Yes	AltaThera: Advisory Board Member; Mezzion Pharma Co: Principal Investigator
Di Lorenzo, Carlo	AAP Section/Council Program Chair	Yes	Abbvie-Ironwood: Consultant; NeurAxis: Consultant; Takeda: Consultant; QOL, Inc: Consultant
El Feghaly, Rana	Faculty	Yes	Merck: Research Grant
Flores, Anthony	Faculty	Yes	GlycosBio, Inc: Research Grant
Foglia, Elizabeth	Faculty	Yes	Chiesi USA: Research grant, Consultant; Medtronic: Consultant
Fox, Claudia	Faculty	Yes	Novo Nordisk: Contractor; Eli Lilly: Contractor
Fuchs, George	Faculty	Yes	Moderna: Research Grant
Fuchs, Molly	Moderator	Yes	Urovant/Syneos Health: Consultant
Golden, William	Faculty	Yes	MJH Life Sciences: Advisory Board Member
Gross, Robert	Faculty	Yes	Rebion: Stockholder
Guglani, Lokesh	Faculty	Yes	Microbion Biosciences: Consultant
Gupta, Malika	Faculty	Yes	Alerje, Inc.: Advisory Board Member
Gwynn, Lisa	Faculty	Yes	Merck: Advisory Board Member
Hammitt, Laura	Faculty	Yes	Merck: Research Grant; AstraZeneca: Research Grant
Hogan, Angela	Planning Group	Yes	GlaxoSmithKline: Speaker Bureau
Hogue, Grant	Faculty	Yes	Medtronic: Consultant
Hubbard, Dena	Faculty	Yes	Abbott Nutrition: Speaker Bureau
Hudson, Jeff	Staff	Yes	CVS: Stockholder
Hunter, Brandon	Faculty	Yes	XN Health: Advisory Board Member; DM1 LLC: Advisory Board Member; KidTech: Advisory Board Member
Jatana, Kris	Faculty	Yes	Marpac Inc.: Royalties; Zotarix LLC: Shareholder; Landsdowne Labs LLC: Stockholder; Tivic Health Systems: Stockholder; Grace Medical: Royalties
Jeewa, Aamir	Faculty	Yes	Ultragenyx: Advisory Board Member; Abbott Industries: Research Grant; Merck: Advisory Board Member; Berlin Heart: Clinical Events Committee Chair
Khalil, Paul	Faculty	Yes	Exo Iris: Contractor
Kirsch, Andrew	Faculty	Yes	Palette Life Science: Consultant; Intuitive Surgical: Speaker Bureau; Global Contenance Inc: Employee/Owner
Lee-Kim, YoungNa	Faculty	Yes	Sanofi Pharmaceutical: Advisory Board Member
Leeds, Stephanie	Faculty	Yes	Regeneron, Inc.: Consultant; Linical, Inc.: Consultant
Lewis, Dalila	Planning Group	Yes	Neurelis: Speaker Bureau
Maguiness, Sheilagh	Faculty	Yes	Stryke Club: Employee/Owner
Major-Kincade, Terri	Faculty	Yes	Proctor and Gamble: Advisory Board Member
Merchant, Nadia	Faculty	Yes	Pfizer: Advisory Board Member; BioMarin: Advisory Board Member; Alexion: Advisory Board Member; Catalyst: Advisory Board Member
Millbrandt, Todd	Faculty	Yes	Medtronic: Consultant; Pathkeeper: Consultant; Depuy Spine: Consultant; Nsite: Consultant; Viking Scientific: Stockholder
Moore, Lindsey	Faculty	Yes	Aimmune: Speaker Bureau; Kenota Health: Principal Investigator; Evidera: Consultant; Genentech: Speaker Bureau
Newland, Jason	Faculty	Yes	Pfizer: Principal Investigator; Moderna: Principal Investigator
Parsi, Linda	Faculty	Yes	Mead Johnson: Speaker Bureau

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Peltier, Christopher	Faculty	Yes	Procter and Gamble: Advisory Board Member; Mead Johnson: Speaker Bureau; By Heart: Research Grant; GSK: Research Grant; Danone Nutrica: Research Grant
Perman, Marissa	Faculty	Yes	Abeona: Consultant; Aegle: Principal Investigator
Prince, Benjamin	Faculty	Yes	Sanofi: Advisory Board Member
Purves, Todd	Faculty	Yes	Abbvie: Principal Investigator; ExstoBio inc: Advisory Board Member
Ramsey, Nicole	Faculty	Yes	Pfizer Pharmaceuticals: Principal Investigator
Raynor, Eileen	Faculty	Yes	Inspire Medical: Principal Investigator
Ross, Kirsten	Faculty	Yes	Johnson & Johnson: Consultant; Medtronic: Consultant
Rossano, Joseph	Moderator	Yes	American Regent: Consultant; AskBio: Consultant; BioMarin: Consultant; Bayer: Consultant; Bristol Myers Squibb: Consultant; Enzyvant: Consultant
Rubinstein Reiss, Dorit	Faculty	Yes	GSK: Stockholder
Schmitz, Jonathan	Faculty	Yes	Biofire / Biomereieux: Research Grant; Genmark / Roche: Research Grant; SASR Health: Research Grant; Quantum Materials Corporation: Research Grant; Karius Diagnostics: Research Grant; Specific Diagnostics: Research Grant; OM-1 / Hologic: Research Grant
Soghier, Lamia	Faculty	Yes	Pyramex: Principal Investigator; Etiometry: Principal Investigator
Sohl, Kristin	Faculty	Yes	Cognoa: Research Grant; Quadrant Biosciences: Advisory Board Member
Song, Clara	Faculty	Yes	Mead Johnson Nutrition: Speaker Bureau
Soslow, Jonathan	Faculty	Yes	Pfizer: Consultant; Sarepta: Consultant; Immunoforge: Consultant; WCG: Consultant
Strominger, Mitchell	Faculty	Yes	Amgen: Speaker Bureau
Stukus, David	Faculty	Yes	ARS Pharmaceuticals: Consultant; DBV Technologies: Principal Investigator
Tong, Carmen	Faculty	Yes	Novo Nordisk: Advisory Board Member
Turek, Joseph	Faculty	Yes	Surge Ingenuity Corp: Stockholder
Tyler, Amy	Faculty	Yes	Biomerieux: Stockholder
Wang, Julie	Faculty	Yes	Aimmune Therapeutics: Research Grant; DBV Technologies: Research Grant; Siolta: Research Grant; Regeneron: Research Grant; ALK Abello: DSMB member; Jubilant HollisterStier: Consultant
Weems, Mark	Faculty	Yes	Abbott Congenital Heart: Speaker Bureau
Yen, Yi-Meng	AAP Section/Council Program Chair	Yes	Smith-Nephew: Consultant
Yoo, Sylvia	Faculty	Yes	Sydnexis: Principal Investigator; Doximity: Stockholder